These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 8387903)

  • 1. Pharmacokinetics and pharmacodynamics of doxorubicin in patients with small cell lung cancer.
    Piscitelli SC; Rodvold KA; Rushing DA; Tewksbury DA
    Clin Pharmacol Ther; 1993 May; 53(5):555-61. PubMed ID: 8387903
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of cyclosporine on the pharmacokinetics of doxorubicin in patients with small cell lung cancer.
    Rushing DA; Raber SR; Rodvold KA; Piscitelli SC; Plank GS; Tewksbury DA
    Cancer; 1994 Aug; 74(3):834-41. PubMed ID: 8039111
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Pharmacokinetic profile of high-dose doxorubicin administered during a 6 h intravenous infusion in breast cancer patients].
    Wihlm J; Limacher JM; Levêque D; Duclos B; Dufour P; Bergerat JP; Methlin G
    Bull Cancer; 1997 Jun; 84(6):603-8. PubMed ID: 9295863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Doxorubicin area under the curve is an important predictor of neutropenia in dogs with naturally occurring cancers.
    Wittenburg LA; Weishaar K; Ramirez D; Gustafson DL
    Vet Comp Oncol; 2019 Jun; 17(2):147-154. PubMed ID: 30638304
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The disposition of doxorubicin on repeated dosing.
    Rushing DA; Piscitelli SC; Rodvold KA; Tewksbury DA
    J Clin Pharmacol; 1993 Aug; 33(8):698-702. PubMed ID: 8408728
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and metabolism of 4'-iodo-4'-deoxy-doxorubicin in humans.
    Robert J; Armand JP; Huet S; Klink-Alakl M; Recondo G; Hurteloup P
    J Clin Oncol; 1992 Jul; 10(7):1183-90. PubMed ID: 1607922
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma pharmacokinetics and pharmacodynamics of a new prodrug N-l-leucyldoxorubicin and its metabolites in a phase I clinical trial.
    de Jong J; Geijssen GJ; Munniksma CN; Vermorken JB; van der Vijgh WJ
    J Clin Oncol; 1992 Dec; 10(12):1897-906. PubMed ID: 1453205
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Doxorubicin clearance in the obese.
    Rodvold KA; Rushing DA; Tewksbury DA
    J Clin Oncol; 1988 Aug; 6(8):1321-7. PubMed ID: 3411343
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population pharmacokinetics of doxorubicin: establishment of a NONMEM model for adults and children older than 3 years.
    Kontny NE; Würthwein G; Joachim B; Boddy AV; Krischke M; Fuhr U; Thompson PA; Jörger M; Schellens JH; Hempel G
    Cancer Chemother Pharmacol; 2013 Mar; 71(3):749-63. PubMed ID: 23314734
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of phenytoin on the pharmacokinetics of doxorubicin and doxorubicinol in the rabbit.
    Cusack BJ; Tesnohlidek DA; Loseke VL; Vestal RE; Brenner DE; Olson RD
    Cancer Chemother Pharmacol; 1988; 22(4):294-8. PubMed ID: 3168142
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical pharmacology of chronic oral etoposide in patients with small cell and non-small cell lung cancer.
    Zucchetti M; Pagani O; Torri V; Sessa C; D'Incalci M; De Fusco M; de Jong J; Gentili D; Martinelli G; Tinazzi A
    Clin Cancer Res; 1995 Dec; 1(12):1517-24. PubMed ID: 9815952
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of low-dose doxorubicin and metabolites in patients with AIDS-related Kaposi sarcoma.
    Joerger M; Huitema AD; Meenhorst PL; Schellens JH; Beijnen JH
    Cancer Chemother Pharmacol; 2005 May; 55(5):488-96. PubMed ID: 15726371
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Doxorubicin and doxorubicinol pharmacokinetics and tissue concentrations following bolus injection and continuous infusion of doxorubicin in the rabbit.
    Cusack BJ; Young SP; Driskell J; Olson RD
    Cancer Chemother Pharmacol; 1993; 32(1):53-8. PubMed ID: 8462124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance.
    Bartlett NL; Lum BL; Fisher GA; Brophy NA; Ehsan MN; Halsey J; Sikic BI
    J Clin Oncol; 1994 Apr; 12(4):835-42. PubMed ID: 8151326
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population pharmacokinetics of doxorubicin, etoposide and ifosfamide in small cell lung cancer patients: results of a multicentre study.
    Freyer G; Tranchand B; Ligneau B; Ardiet C; Souquet PJ; Court-Fortune I; Riou R; Rebattu P; Boissel JP; Trillet-Lenoir V; Girard P
    Br J Clin Pharmacol; 2000 Oct; 50(4):315-24. PubMed ID: 11012554
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population pharmacokinetics and pharmacodynamics of doxorubicin and cyclophosphamide in breast cancer patients: a study by the EORTC-PAMM-NDDG.
    Joerger M; Huitema AD; Richel DJ; Dittrich C; Pavlidis N; Briasoulis E; Vermorken JB; Strocchi E; Martoni A; Sorio R; Sleeboom HP; Izquierdo MA; Jodrell DI; Féty R; de Bruijn E; Hempel G; Karlsson M; Tranchand B; Schrijvers AH; Twelves C; Beijnen JH; Schellens JH;
    Clin Pharmacokinet; 2007; 46(12):1051-68. PubMed ID: 18027989
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population pharmacokinetic modelling of doxorubicin and doxorubicinol in children with cancer: is there a relationship with cardiac troponin profiles?
    Kunarajah K; Hennig S; Norris RLG; Lobb M; Charles BG; Pinkerton R; Moore AS
    Cancer Chemother Pharmacol; 2017 Jul; 80(1):15-25. PubMed ID: 28444427
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Doxorubicin and doxorubicinol: intra- and inter-individual variations of pharmacokinetic parameters.
    Jacquet JM; Bressolle F; Galtier M; Bourrier M; Donadio D; Jourdan J; Rossi JF
    Cancer Chemother Pharmacol; 1990; 27(3):219-25. PubMed ID: 2265458
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Toxicokinetics of the active doxorubicin metabolite, doxorubicinol, in sulphur-crested cockatoos (Cacatua galerita).
    Gilbert CM; Filippich LJ; McGeary RP; Charles BG
    Res Vet Sci; 2007 Aug; 83(1):123-9. PubMed ID: 17197005
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epirubicin. Clinical pharmacology and dose-effect relationship.
    Robert J
    Drugs; 1993; 45 Suppl 2():20-30. PubMed ID: 7693418
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.